Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

What Do Doctors Think About Biosimilars?

1,867 views

Published on

As the global biosimilars market opens up, what do physicians faced with choosing between prescribing a brand-name biologic or biosimilar think – and know?

Published in: Healthcare
  • I am a living proof that Chief Dr Lebo herbal WORKS and can be incredibly useful to couples with infertility issues. My husband and I found out I was pregnant after over 6 years of desperately trying. We were both checked but the doctors could find nothing. I prayed and prayed, Fasted but nothing happened. I ordered for Chief Dr Lebo herbal medication after hearing numerous success stories of other women using his recommendations. As soon as I started implementing the instructions, including doing some acupuncture with his guidance, I could see a dramatic improvement of my health within days and within 2 months we had a new little one on the way! I have gone through years of disappointment never believing it could happen to. It did. All thanks to Chief Dr. Lebo Contact Chief Dr Lebo on via Email: chief.dr.lebo1@gmail.com or Call & WhatsApp+27631394550
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here

What Do Doctors Think About Biosimilars?

  1. 1. What Do Doctors Think About Biosimilars? Powered by Small World Social www.biolink.us
  2. 2. In March 2015, the Alliance for Safe Biologic Medicines (ASBM), released results from their survey of 400 US physicians on biologics medicines labeling. Powered by Small World Social www.biolink.us
  3. 3. The web-based survey was conducted before the FDA approved Zarxio, the first biosimilar in the US, and sought the view of dermatologists, endocrinologists, oncologists, nephrologists, neurologists and rheumatologists. It found… Powered by Small World Social www.biolink.us
  4. 4. Powered by Small World Social considered it important for a biosimilar’s product label to clearly indicate that it is a biosimilar. 90% of correspondents 4Biolink.us
  5. 5. Powered by Small World Social it important for the biosimilar label to include the biosimilar sponsor’s analytical data demonstrating its analytical similarity to the reference product 82% thought 5Biolink.us
  6. 6. Powered by Small World Social It important that the biosimilar label includes the clinical data, if any, submitted to the FDA by the sponsor again demonstrating that it is highly similar to the reference product 83% thought 6Biolink.us
  7. 7. Powered by Small World Social It important that the label explicitly state that the specific indications or conditions of use approved for the originator product that are not approved for the biosimilar product 79% found 7Biolink.us
  8. 8. In 2013, the ASBM also surveyed 470 European physicians, from the United Kingdom, France, Germany, Italy and Spain to gauge their views on non-proprietary naming of biological medicines. Powered by Small World Social www.biolink.us
  9. 9. The survey highlighted the lack of awareness about biosimilars amongst prescribing specialist physicians and the need for further education. It found… Powered by Small World Social www.biolink.us
  10. 10. Powered by Small World Social said they are ‘familiar’ with biosimilars, but only have a basic understanding 54% of respondents 10Biolink.us
  11. 11. Powered by Small World Social were unable to define biosimilars 20% of the physicians 11Biolink.us
  12. 12. Powered by Small World Social had never heard of biosimilars 4% of respondents 12Biolink.us
  13. 13. Powered by Small World Social were ‘very familiar’, with a complete understanding of biosimilars 22% of the physicians 13Biolink.us
  14. 14. Meanwhile, a study conducted by the Tufts Center of the Study of Drug Development, at Tufts University in Boston, found that… Powered by Small World Social www.biolink.us
  15. 15. Powered by Small World Social While the majority of physicians, 70%, surveyed said they would be likely to prescribe biosimilars to a new patient, the overall lack of familiarity with the new products among specialist physicians could slow the uptake of biosimilars in the U.S. 15Biolink.us
  16. 16. Powered by Small World Social www.biolink.us Want to read more about biosimilars? Visit: https://www.smallworldsocial.com/biolink/ to get the latest in biosimilar news curated from around the world

×